These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 11197218)

  • 1. Successful treatment of multiple myeloma--associated amyloidosis by interferon-alpha, dimethyl sulfoxide, and VAD (vincristine, adriamycin, and dexamethasone).
    Ichida M; Imagawa S; Ohmine K; Komatsu N; Hatake K; Ozawa K; Miura Y
    Int J Hematol; 2000 Dec; 72(4):491-3. PubMed ID: 11197218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [IgM-lambda multiple myeloma presenting with systemic amyloidosis].
    Higeta D; Yokohama A; Osaki Y; Tahara K; Mawatari M; Sekigami T; Koiso H; Saito T; Uchiumi H; Handa H; Karasawa M; Murakami H; Hirato J; Tsukamoto N; Nojima Y
    Rinsho Ketsueki; 2009 Dec; 50(12):1711-4. PubMed ID: 20068279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A patient with AL amyloidosis and severe factor X deficiency has been in complete haematological remission with normal factor X activity for 7 years following high-dose chemotherapy. A case study and literature review].
    Adam Z; Matýková M; Krejcí M; Pour L; Kissová J; Slechtová M; Chlupová G; Stavarová Y; Simonides J; Penka M; Mayer J; Hájek R
    Vnitr Lek; 2010 Jan; 56(1):67-78. PubMed ID: 20184115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Improved prognosis of generalized AL-amyloidosis in a patient with multiple myeloma treated according to the VAD protocol].
    Sarkisova IA; Rameev VV; Kozlovskaia LV; Andreeva NE
    Ter Arkh; 2003; 75(8):81-2. PubMed ID: 14520860
    [No Abstract]   [Full Text] [Related]  

  • 5. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
    Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
    Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Multiple myeloma of the IgD-lambda type invading CNS].
    Kitamura K; Takeuchi J; Kanbe E; Oka H; Saiki M; Aikawa S; Kura Y; Hatta Y; Yamazaki T; Ito T; Sawada U; Horie T
    Rinsho Ketsueki; 2004 Oct; 45(10):1124-8. PubMed ID: 15553049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma.
    Cook G; Clark RE; Morris TC; Robertson M; Lucie NP; Anderson S; Paul J; Franklin IM
    Br J Haematol; 2004 Sep; 126(6):792-8. PubMed ID: 15352982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
    Hussein MA; Wood L; Hsi E; Srkalovic G; Karam M; Elson P; Bukowski RM
    Cancer; 2002 Nov; 95(10):2160-8. PubMed ID: 12412170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New protocols for myeloma chemotherapy plus IFN alpha].
    Kitani T
    Rinsho Ketsueki; 1993 Apr; 34(4):455-9. PubMed ID: 8510333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial.
    Rifkin RM; Gregory SA; Mohrbacher A; Hussein MA
    Cancer; 2006 Feb; 106(4):848-58. PubMed ID: 16404741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High dose simvastatin does not reverse resistance to vincristine, adriamycin, and dexamethasone (VAD) in myeloma.
    van der Spek E; Bloem AC; Sinnige HA; Lokhorst HM
    Haematologica; 2007 Dec; 92(12):e130-1. PubMed ID: 18055977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Testicular involvement in IgD multiple myeloma].
    Kawauchi K; Ogasawara T; Yasuyama M; Ohkawa S; Aiba M
    Rinsho Ketsueki; 2001 Nov; 42(11):1128-33. PubMed ID: 11808083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy of resistant multiple myeloma with vincristine, adriamycin and dexamethasone (VAD).
    Maniatis A; Stamatellou M; Papanastasiou K
    Chemioterapia; 1987 Jun; 6(2 Suppl):727-8. PubMed ID: 3509532
    [No Abstract]   [Full Text] [Related]  

  • 14. [A case of gastric amyloidosis developing into Bence-Jones type multiple myeloma, treated effectively by cyclo-VAMP chemotherapy].
    Ayabe T; Maekawa I; Ashida T; Taruishi M; Shibata Y; Namiki M
    Gan To Kagaku Ryoho; 1993 Dec; 20(15):2399-403. PubMed ID: 8259860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Rapid progression of systemic amyloidosis after high-dose corticosteroid therapy in multiple myeloma].
    Kanoh T; Yogo K; Ohnaka T
    Rinsho Ketsueki; 1990 Oct; 31(10):1736-9. PubMed ID: 2255065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lower cardiotoxicity of adriamycin during continuous administration in patients with refractory multiple myeloma treated with cyclophosphamide, vincristine, adriamycin and dexamethasone (C-VAD)].
    Adam Z; Elbl L; Vorlícek J; Hájek R; Tomíska M; Hejlová N; Králová E; Novotná H
    Vnitr Lek; 1994 Aug; 40(8):506-12. PubMed ID: 7941437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
    Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J;
    Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma.
    Corso A; Barbarano L; Zappasodi P; Cairoli R; Alessandrino EP; Mangiacavalli S; Ferrari D; Fava S; Fiumanò M; Frigerio G; Isa L; Luraschi A; Klersy C; De Paoli A; Vergani C; Banfi L; Perego D; Ucci G; Pinotti G; Savarè M; Uziel L; Vismara A; Morra E; Lazzarino M
    Haematologica; 2004 Sep; 89(9):1124-7. PubMed ID: 15377474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid deposition of systemic myeloma-associated amyloidosis excludes actinic elastotic material.
    Wada N; Fujimoto N; Komatsu T; Tajima S; Ishibashi A
    Eur J Dermatol; 2002; 12(6):607-8. PubMed ID: 12459542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Aggressive transformation and extramedullary tumor formation in IgA-lambda multiple myeloma].
    Tanigawa M; Tamaki S; Fujieda A; Miyashita H; Tanaka K; Ichioka M; Taniguchi M; Tsuji K; Miyanishi E
    Rinsho Ketsueki; 2000 Aug; 41(8):635-40. PubMed ID: 11020990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.